Preclinical studies have shown that venetoclax is active for leukemias in the high-risk genetic group, such as KMT2A-rearranged ALL [108], hypodiploid ALL [38], BCR/ABL-positive ALL [109], TCF3/HLF-rearranged ALL [63], and T-ALL (including ETP-ALL) [110,111]. Here, KMT2A is linked to acute lymphoblastic leukemia.